Glycoproteinoses - Sugar-Coated Chaos
- Lysosomal storage disorders caused by deficient glycoprotein-degrading enzymes, leading to the accumulation of oligosaccharides with attached peptide fragments.

-
Aspartylglucosaminuria:
- Defect: Aspartylglucosaminidase (AGA).
- Features: Progressive neurodegeneration, coarse facies, connective tissue abnormalities, intellectual disability starting at age 2-4.
-
Fucosidosis:
- Defect: α-L-Fucosidase (FUCA1).
- Features: Coarse facies, growth retardation, psychomotor retardation, visceromegaly.
⭐ Angiokeratomas are a key feature of Fucosidosis, similar to Fabry disease, but Fucosidosis presents with coarser facial features and intellectual disability.
The Disorders - Rogues' Gallery
Glycoproteinoses are a group of lysosomal storage disorders caused by defects in glycoprotein degradation. This leads to the accumulation of oligosaccharides and glycopeptides in lysosomes, resulting in multisystemic clinical manifestations.
| Disorder | Deficient Enzyme | Accumulated Substrate | Key Clinical Features |
|---|---|---|---|
| Aspartylglucosaminuria | Aspartylglucosaminidase | Aspartylglucosamine | Late-onset coarse facies, intellectual disability, angiokeratomas, macroglossia. |
| Fucosidosis | α-L-Fucosidase | Fucose-containing glycolipids & oligosaccharides | Coarse facies, growth retardation, dysostosis multiplex, angiokeratomas, ↑ sweat salinity. |
| Schindler Disease | α-N-Acetylgalactosaminidase (α-NAGA) | Glycopeptides with α-N-acetylgalactosaminyl termini | Type I (infantile): neuroaxonal dystrophy, rapid neurodegeneration. Type II (adult): milder, angiokeratoma corporis diffusum. |
| Sialidosis (Mucolipidosis I) | α-N-Acetylneuraminidase (Sialidase) | Sialyloligosaccharides | Type I: normal intelligence, myoclonus, ataxia, cherry-red spot. Type II: infantile onset, coarse facies, dysostosis multiplex. |
⭐ Exam Favourite: The presence of a macular cherry-red spot on fundoscopy is a classic finding in Sialidosis (Type I), similar to Tay-Sachs disease, but distinguished by the associated myoclonus and normal early development.
Diagnosis & Management - The Clinician's Playbook
-
Diagnosis
- Screening: Urinary oligosaccharide analysis.
- Definitive Diagnosis: Enzyme activity assays in cultured fibroblasts or leukocytes.
- Confirmation: Molecular genetic testing for specific gene mutations.
-
Management
- Primary Approach: Symptomatic and supportive care.
- Managing seizures, recurrent infections, and skeletal abnormalities.
- Therapeutic Options:
- Hematopoietic stem cell transplantation (HSCT) has shown limited success in some cases (e.g., fucosidosis).
- Enzyme replacement therapy (ERT) and chaperone therapies are largely investigational.
- Primary Approach: Symptomatic and supportive care.
⭐ Exam Favorite: Aspartylglucosaminuria has a significantly high prevalence in the Finnish population due to a founder effect.
High‑Yield Points - ⚡ Biggest Takeaways
- Glycoproteinoses are a group of autosomal recessive disorders resulting from defects in glycoprotein catabolism.
- This leads to lysosomal accumulation of glycans or glycopeptides, causing widespread cellular dysfunction.
- Clinical overlap with MPS is significant: coarse facial features, dysostosis multiplex, and psychomotor retardation.
- Distinguishing features can include angiokeratomas, hearing loss, and myoclonus.
- Diagnosis is confirmed by detecting oligosaccharides in urine and through specific enzyme activity assays.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app